STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYTK
  4. [Form 4] CYTOKINETICS INC Insider Trading Activity

Cytokinetics EVP Callos sells 10K shares at $70

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) insider Andrew Callos, EVP and Chief Commercial Officer, exercised 10,000 Non-Qualified Stock Options on 2026-08-31 at an exercise price of $23.26 per share, acquiring 10,000 common shares. On the same date, he sold 10,000 common shares at $70.24 per share, leaving 0 options from this grant outstanding. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Callos Andrew
Role EVP, Chief Commercial Officer
Sold 10,000 shs ($702K)
Approx. gross sale proceeds $702K
Approx. exercise cost $233K
Approx. pre-tax spread $470K
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (Right to Buy) F1 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $23.26 $233K
Sale Common Stock 10,000 $70.24 $702K
Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 58,555 shares (Direct)
Footnotes (1)
  1. F1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Options exercised 10,000 shares Non-Qualified Stock Option (Right to Buy) exercised on 2026-08-31
Exercise price $23.26 per share Conversion or exercise price of the stock options
Shares sold 10,000 shares Common Stock sale on 2026-08-31
Sale price $70.24 per share Price for the 10,000 Common Stock shares sold
Options remaining from this grant 0 shares Total shares following option exercise transaction
Non-Qualified Stock Option (Right to Buy) financial
"security_title: "Non-Qualified Stock Option (Right to Buy)""
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
Sale in open market or private transaction financial
"transaction_code_description: "Sale in open market or private transaction""

FAQ

What transactions did CYTK executive Andrew Callos report on this Form 4?
Andrew Callos reported exercising 10,000 stock options at an exercise price of $23.26 per share and selling 10,000 shares of CYTK common stock at $70.24 per share on 2026-08-31.

How many CYTK stock options did Andrew Callos exercise and at what price?
He exercised 10,000 Non-Qualified Stock Options (Right to Buy) at an exercise price of $23.26 per share, converting them into 10,000 shares of CYTOKINETICS INC common stock.

How many CYTK shares did Andrew Callos sell and at what price?
He sold 10,000 shares of CYTK common stock at a reported price of $70.24 per share on 2026-08-31, in a transaction coded as a sale in open market or private transaction.

Were Andrew Callos’s CYTK transactions under a Rule 10b5-1 plan?
Yes. The Form 4 indicates the Rule 10b5-1 checkbox is marked, meaning the reported transactions were effected pursuant to a pre-established trading plan under Rule 10b5-1.

What happened to Andrew Callos’s CYTK stock options after these transactions?
After exercising 10,000 Non-Qualified Stock Options tied to this grant, his reported holdings of that specific option position are 0 shares following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Callos Andrew
(Last)(First)(Middle)
350 OYSTER POINT BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026M10,000A$23.2668,555D
Common Stock08/31/2026S10,000D$70.2458,555D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (Right to Buy)$23.2608/31/2026M10,00003/31/2022(1)03/31/2031Common Stock10,000$00D
Explanation of Responses:
1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
/s/ John O. Faurescu, attorney-in-fact for Mr. Callos08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR